NEW YORK, May 30, 2024 /PRNewswire/ -- Blue Owl Capital Inc. ("Blue Owl") (NYSE: OWL) today announced the pricing of the offering of $250,000,000 of 6.250% Senior Notes due 2034 (the "notes") by Blue Owl Finance LLC, its indirect subsidiary, at an issue price of 100.355%, plus accrued interest, if any, from April 18, 2024. The notes are being offered as additional notes under the same indenture as the previously issued $750,000,000 aggregate principal amount of its 6.250% Senior Notes due 2034 and will be t ...

NEW YORK, May 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether bluebird and certain of its officers ...

NEW YORK, May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE).Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bluebird-bio-loss-submission-form/?id=80713&from=4CLASS PERIOD: April 24, 2023 to Decem ...

LOS ANGELES, May 16, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE).Class Period: April 24, 2023 – December 8, 2023Lead Plaintiff Deadline: May 28, 2024If you wish to serve as lead plaintiff of the bluebird lawsuit, you can submit your contact information at www.glancylaw.com/cases/bluebird-bio-Inc-1/. You can al ...

It won't be easy for the company to bounce back.Being a highly innovative company isn't a sufficient condition for success in the biotech industry. Bluebird Bio (BLUE), a small-cap gene-editing specialist, is a good example of this. Though the company has developed groundbreaking therapies, the stock has significantly lagged the market in recent years. Still, if Bluebird Bio can turn things around, the company could deliver explosive returns to investors who initiate a position today. Is Bluebird Bio worth ...

bluebird bio, Inc. (NASDAQ:BLUE) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Courtney O'Leary - IR Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer Chris Krawtschuk - CFO Conference Call Participants Jason Gerberry - Bank of America Jack Allen - Baird Gena Wang - Barclays Eric Joseph - JPMorgan Eric Schmidt - Cantor Fitzgerald Lisa Walter - RBC Capital Markets Brooke Schuster - William Blair Operator Thank you for standing by, and welcome to the blueb ...

bluebird bio (BLUE) registered revenues of $18.6 million in the first quarter, up from $2.4 million recorded in the year-ago quarter and beating the Zacks Consensus Estimate of $18 million.The $16.2-million upside can be attributed to increased Zynteglo product revenues.The FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusion on Aug 17, 2022, and Skysona for treating early, active cerebral adrenoleukodystrophy (CALD) on Sept ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________ Securities registered pursuant to Section 12(b) of the Act: FORM 8-K __________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 __________________________ Delaware (State or Other Jurisdiction 455 Grand Union Boulevard, Somerville, MA 02145 (Address of Principal Executive Offices) (Zip Code) blue ...

bluebird bio’s (BLUE) shares have lost 25.4% year to date compared with the industry’s decline of 7.9%.As of now, the going is challenging for bluebird. While the approval of its three gene therapies bodes well, the uptake of the same has not gained traction as expected.Image Source: Zacks Investment ResearchThe FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusion on Aug 17, 2022. It also approved Skysona for treating early, ...

Who wins this face-to-face between two beaten-down biotechs?If there is one thing Bluebird Bio (BLUE -5.17%) and Novavax (NVAX -0.47%) have in common, other than their belonging to the biotech industry, it is that both have seen their shares drop catastrophically in recent years. Bluebird's stock is down by 91% in the past three years, while Novavax's has declined by 97%.The market doesn't have much faith in either company, but if they can turn things around, opportunistic investors who initiate positions n ...